메뉴 건너뛰기




Volumn 3, Issue 4, 2003, Pages 247-248

Thalidomide: A step forward in the treatment of malignant monoclonal gammopathies

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BORTEZOMIB; CLADRIBINE; CYTOTOXIC AGENT; DEXAMETHASONE; FLUDARABINE; IMMUNOMODULATING AGENT; PROTEINASE INHIBITOR; RITUXIMAB; THALIDOMIDE;

EID: 0037359123     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-9655(11)70186-5     Document Type: Note
Times cited : (9)

References (21)
  • 1
    • 0014661330 scopus 로고
    • Treatment of multiple myeloma: Combination chemotherapy with different melphalan dose regimens
    • Alexanian R, Haut A, Khan AU, et al. Treatment of multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680-1696.
    • (1969) JAMA , vol.208 , pp. 1680-1696
    • Alexanian, R.1    Haut, A.2    Khan, A.U.3
  • 2
    • 17944381821 scopus 로고    scopus 로고
    • Increased conventional chemotherapy does not improve survival in multiple myeloma: Long-term results of two PETHEMA trials including 914 patients
    • Bladé J, San Miguel JF, Fontanillas M, et al. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Hematol J 2001; 2:272-278.
    • (2001) Hematol. J. , vol.2 , pp. 272-278
    • Bladé, J.1    San Miguel, J.F.2    Fontanillas, M.3
  • 3
    • 0344076348 scopus 로고    scopus 로고
    • Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials
    • The Myeloma Trialists' Collaborative Group
    • The Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998; 16:3832-3842.
    • (1998) J. Clin. Oncol. , vol.16 , pp. 3832-3842
  • 4
    • 0033764086 scopus 로고    scopus 로고
    • High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution
    • Bladé J, Esteve J, Rives S, et al. High-dose therapy autotransplantation/ intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant 2000; 26:845-849.
    • (2000) Bone Marrow Transplant , vol.26 , pp. 845-849
    • Bladé, J.1    Esteve, J.2    Rives, S.3
  • 5
    • 0034954989 scopus 로고    scopus 로고
    • Impact of complete remission with intensive therapy in patients with responsive multiple myeloma
    • Alexanian R, Weber D, Giralt S, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27:1037-1042.
    • (2001) Bone Marrow Transplant , vol.27 , pp. 1037-1042
    • Alexanian, R.1    Weber, D.2    Giralt, S.3
  • 6
    • 0012961309 scopus 로고    scopus 로고
    • High-dose therapy and autologous transplantation
    • Mehta J, Singhal S, eds. London: Martin Dunitz
    • Singhal S. High-dose therapy and autologous transplantation. In: Mehta J, Singhal S, eds. Myeloma. London: Martin Dunitz; 2002:327-347.
    • (2002) Myeloma , pp. 327-347
    • Singhal, S.1
  • 7
    • 0012905046 scopus 로고    scopus 로고
    • Waldenström's macroglobulinemia
    • Mehta J, Singhal S, eds. London:. Martin Dunitz
    • Dimopoulos MA. Waldenström's macroglobulinemia. In: Mehta J, Singhal S, eds. Myeloma. London: Martin Dunitz; 2002:466-480.
    • (2002) Myeloma , pp. 466-480
    • Dimopoulos, M.A.1
  • 8
    • 0028362802 scopus 로고
    • Bone marrow angiogenesis and progression in multiple myeloma
    • Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87:503-508.
    • (1994) Br. J. Haematol. , vol.87 , pp. 503-508
    • Vacca, A.1    Ribatti, D.2    Roncali, L.3
  • 9
    • 0032748385 scopus 로고    scopus 로고
    • Antitumor activity of thalidomide in refractory multiple myeloma
    • Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-1571.
    • (1999) N. Engl. J. Med. , vol.341 , pp. 1565-1571
    • Singhal, S.1    Mehta, J.2    Desikan, R.3
  • 10
    • 0034116457 scopus 로고    scopus 로고
    • Frequent good partial remissions from thalidomide including best responses ever in patients with advanced refractory and relapsed multiple myeloma
    • Juliusson G, Gelsing F, Toresson I, et al. Frequent good partial remissions from thalidomide including best responses ever in patients with advanced refractory and relapsed multiple myeloma. Br J Haematol 2000; 109:89-96.
    • (2000) Br. J. Haematol. , vol.109 , pp. 89-96
    • Juliusson, G.1    Gelsing, F.2    Toresson, I.3
  • 11
    • 0034014693 scopus 로고    scopus 로고
    • Therapy with thalidomide in refractory multiple myeloma patient - The revival of an old drug
    • Kneller A, Raanani P, Hardan I, et al. Therapy with thalidomide in refractory multiple myeloma patient - the revival of an old drug. Br J Haematol 2000; 108:391-393.
    • (2000) Br. J. Haematol. , vol.108 , pp. 391-393
    • Kneller, A.1    Raanani, P.2    Hardan, I.3
  • 12
    • 0034585033 scopus 로고    scopus 로고
    • Thalidomide in patients with advanced multiple myeloma
    • Yakoub-Agha I, Moreau P, Leyvraz S, et al. Thalidomide in patients with advanced multiple myeloma. Hematol J 2000; 1:186-189.
    • (2000) Hematol. J. , vol.1 , pp. 186-189
    • Yakoub-Agha, I.1    Moreau, P.2    Leyvraz, S.3
  • 13
    • 0035880229 scopus 로고    scopus 로고
    • Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients
    • Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98:492-494.
    • (2001) Blood , vol.98 , pp. 492-494
    • Barlogie, B.1    Desikan, R.2    Eddlemon, P.3
  • 14
    • 0035211881 scopus 로고    scopus 로고
    • Novel therapies targeting the myeloma cell and its bone marrow pie microenvironment
    • Hideshima T, Chauban D, Podar K, et al. Novel therapies targeting the myeloma cell and its bone marrow pie microenvironment. Semin Oncol 2001; 28:607-612.
    • (2001) Semin. Oncol. , vol.28 , pp. 607-612
    • Hideshima, T.1    Chauban, D.2    Podar, K.3
  • 15
    • 0034885073 scopus 로고    scopus 로고
    • Thalidomide in the management of multiple myeloma
    • Barlogie B, Zangari M, Spencer T, et al. Thalidomide in the management of multiple myeloma. Semin Hematol 2001; 38:250-259.
    • (2001) Semin. Hematol. , vol.38 , pp. 250-259
    • Barlogie, B.1    Zangari, M.2    Spencer, T.3
  • 16
    • 0034995376 scopus 로고    scopus 로고
    • Thalidomide in multiple myeloma: Lack of response of soft-tissue plasmacytomas
    • Bladé J, Perales M, Rosiñol L, et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 2001; 113:422-424.
    • (2001) Br. J. Haematol. , vol.113 , pp. 422-424
    • Bladé, J.1    Perales, M.2    Rosiñol, L.3
  • 17
    • 0034861712 scopus 로고    scopus 로고
    • Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma
    • Avigdor A, Raanani P, Levi I, et al. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma 2001; 42:683-687.
    • (2001) Leuk. Lymphoma , vol.42 , pp. 683-687
    • Avigdor, A.1    Raanani, P.2    Levi, I.3
  • 18
    • 0035881040 scopus 로고    scopus 로고
    • Treatment of Waldenström's macroglobulinemia with thalidomide
    • Dimopoulos MA, Zomas A, Viniou NA, et al. Treatment of Waldenström's macroglobulinemia with thalidomide. J Clin Oncol 2001; 19:3596-3601.
    • (2001) J. Clin. Oncol. , vol.19 , pp. 3596-3601
    • Dimopoulos, M.A.1    Zomas, A.2    Viniou, N.A.3
  • 19
    • 0037359277 scopus 로고    scopus 로고
    • Tolerability and efficacy of thalidomide for treatment of patients with AL amyloidosis
    • Seldin DC, Choufani EB, Dember LM, et al. Tolerability and efficacy of thalidomide for treatment of patients with AL amyloidosis. Clin Lymphoma 2003; 3:241-246.
    • (2003) Clin. Lymphoma , vol.3 , pp. 241-246
    • Seldin, D.C.1    Choufani, E.B.2    Dember, L.M.3
  • 20
    • 0037097843 scopus 로고    scopus 로고
    • Autologous stem cell transplantation for primary systemic amyloidosis
    • Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99:4276-4282.
    • (2002) Blood , vol.99 , pp. 4276-4282
    • Comenzo, R.L.1    Gertz, M.A.2
  • 21
    • 0030895545 scopus 로고    scopus 로고
    • A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine
    • Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336:1202-1207.
    • (1997) N. Engl. J. Med. , vol.336 , pp. 1202-1207
    • Kyle, R.A.1    Gertz, M.A.2    Greipp, P.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.